Abbott and the Abbott Fund donate $1 million to support Hurricane Harvey relief efforts
- Details
- Category: Abbott
Abbott (NYSE: ABT) and its foundation, the Abbott Fund, are providing $1 million in grants and healthcare and nutrition products to help deliver immediate relief following Hurricane Harvey and the devastating flooding affecting Texas and Louisiana. The Abbott Fund is providing $900,000 in grants to the American Red Cross, Americares and Direct Relief. Abbott is donating $100,000 in healthcare and nutrition products to relief organizations providing on-the-ground support in affected communities.
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019)
- Details
- Category: Novartis
First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2].
Novartis announced that the US Food and Drug Administration (FDA) has approved Kymriah(TM)(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy,
Novartis announced that the US Food and Drug Administration (FDA) has approved Kymriah(TM)(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy,
Merck collaborates with angiex to speed clinical readiness of new cancer therapy
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibodydrug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
- Details
- Category: AstraZeneca
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD.
Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
- Details
- Category: Novo Nordisk
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain.
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)(1), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.
Novartis appoints Bertrand Bodson as Chief Digital Officer
- Details
- Category: Novartis
Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis. He will join Novartis on January 1, 2018, and will be responsible for creating and executing a company-wide digital strategy in close collaboration with the Executive Committee of Novartis,
More Pharma News ...
- Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
- Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ metastatic breast cancer
- Amgen and Humana partner for improved health outcomes and efficiency
- Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
- Lyfebulb-Novo Nordisk Innovation Award 2017
- Repatha® (evolocumab) phase 3 cognitive function study results published in the New England Journal of Medicine
- Bristol-Myers Squibb announces topline results from CheckMate -214